ADMETECH FOUNDATION’S GPS – GOALS AND BACKGROUND: The goal of the Global Prostate Cancer Summit (GPS) – integration of imaging with other precision diagnostics and treatment – represents a natural evolution of the AdMeTech Foundation’s programs. Since its creation in 1997 as a non-profit 501c3 organization, AdMeTech has been leading national and international groundbreaking programs in research and medical education, public awareness and advocacy, and health equity. AdMeTech pioneered-
- Original research, development and testing of precision prostate MRI and image-guided robotics for biopsy and treatment since 1998.
- Original research, development and evaluation of molecular imaging, with the primary focus on PSMA imaging since 2001.
- PI-RADS standardization of prostate MR, which in turn, enabled multi-center clinical evaluation and large-scale implementation since 2010.
Since its establishment in 2016, AdMeTech Foundation’s GPS has been leading medical education and research in integrated precision diagnostics (radiogenomics specifically and multiomics in general) for precision treatment.
Based on the findings and recommendations of GPS 2022, AdMeTech created International Working Group on Image-Guided Focal Treatment of Prostate Cancer, which has been instrumental in prioritizing development of short-term, image-based patient outcomes for expediting large-scale clinical evaluation and adoption of partial ablation (“male lumpectomy”).
Between 2024 and 2025, AdMeTech’s Working Group designed and initiated pilot studies for assessment of patients after focal treatment, with the following goals:
- To evaluate the role of molecular imaging; and
- To develop and test a broadly accepted, standardized approach to MRI reporting (PI-MAPS, or Prostate Imaging-MRI Assessment Post-ablation Scoring System).
EXECUTIVE SUMMARY – GPS 2025: This virtual event took place on September 15-17, 2025. Building on the success between 2016 and 2024, GPS 2025 had over 60 scientific presentations and 400 international registrants, representing every key clinical expertise and expanding a cross-disciplinary dialogue.
GPS 2025 reviewed the current standard of care and emerging advances in prostate cancer management, including:
- “Smart” screening, integrating PSA testing with imaging and/or liquid biomarkers;
- Precision diagnosis and its integration with individualized management strategies for localized and advanced disease;
- Image-guided focal treatment and partial ablation, including progress report, recommendations and planned research of the AdMeTech’s Working Group; and
- The critical role of bioinformatics, artificial intelligence, machine and deep learning for data integration, underpinning clinical decisions for every stage of patient care.
Similarly to the past annual events, GPS 2025 made a significant impact on the current state of the art and future vision for precision care of prostate cancer, had extensive participation of the international key opinion leaders (KOLs), and offered high visibility of the presented novel ideas, research and innovations during and after the event. GPS 2025’s International Organizing Council (IOC) ensured the highest global participation in this event’s history, with over 400 registrants, mostly physicians (compared to about 300 participants in 2023 and 2024).
High Impact on the state of the art and future vision for prostate cancer care: GPS 2025 has had a consistent and positive response to the event content from general attendees, faculty, and sponsors – regarding the quality of speakers, program and discussions.
- Participating physicians and scientists have reported that this event has made a strong impact on their clinical practice, and general strategy and novel ideas for research.
- Industry leaders have reported a direct and strong impact of this event on their short- and long-term strategy for product development, related research, positioning and large-scale clinical adoption.
- All participants reported multiple networking opportunities that played an important role in establishing new collaborations and partnerships, including those with other Summit participants.
- Cross-disciplinary clinical and scientific dialogue among academic and industry leaders and related consensus on the best emerging clinical practices and research priorities has been effectively maintained – if not enhanced – in a virtual setting.
- Expansion of partnership with Grand Rounds in Urology (GRU), resulting in the post-event online publication of scientific presentation videos and reaching over 15,000 physicians internationally.
- GRU’s Editor-in-Chief, Dr. David Crawford, established AdMeTech’s collaboration with GRU, serving as the Media Partner since 2018. After GPS 2025, Dr. Crawford pointed out the continuous high viewing rate of this event and invited AdMeTech to continue partnership with GRU to ensure “the semination of information from your meeting, which I really believe is the best in the country for prostate cancer”.
Extensive participation of the key opinion leaders (KOLs) of multiple clinical subspecialties: Unlike most prostate cancer meetings, GPS brought together KOLs, representing every clinical expertise involved in prostate cancer care and serving as the key leaders of multiple academic institutions and major professional societies.
- Participation of the KOLs has been instrumental in the development and implementation of a multidisciplinary consensus on the best clinical practices and research priorities.
- GPS 2025 had extensive representation from the committees and organizations developing the cutting-edge clinical guidelines or funding research – including, but not limited to, American College of Radiology (ACR), Radiologic Society of North America (RSNA), National Comprehensive Cancer Network (NCCN), European Association of Urology (EAU), American Urologic Association (AUA), American Society for Radiation Oncology (ASTRO), European Society for Medical Oncology (ESMO), and other organizations in radiology, urology, medical oncology, pathology, and radiation oncology
An important opportunity to influence the influencers: Extensive exposure of presentations during the Summit. Participation of the international, multi-disciplinary KOLs has created a strong positioning of the presented innovations and related data. For all speakers and sponsors in 2025, GPS organizers have offered presentations during the main scientific program for maximum exposure.
High rate of faculty retention: Many GPS speakers have been participating in this annual event since the time of its establishment in 2016. They have been serving as volunteers for the Summit Governing Board, Steering Committee and International Organizing Council.
Increased attendance: Over 400 attendees registered in 2025 (compared to 300 in 2024), reflecting a rapidly growing international participation of physicians. Several speakers, excited about the GPS 2023 and GPS 2024, volunteered to serve on the International Organizing Council (IOC) for GPS 2025 and GPS 2026 to bring the high-quality education offered by the Summit to their regions and countries. IOC has played the key role in expanding global physicians’ participation, particularly from the Middle East, Africa, Eastern and Central Europe, Central and South America, and Asia, in addition to the previously actively participating regions (US, Canada, Western Europe, and Australia).
GPS 2025, similarly to the past annual events, had the following hallmarks:
- Stimulating cross-disciplinary consensus on the best emerging clinical practices and research priorities; and
- Expediting and ensuring networking between speakers, including KOLs, and sponsors (via break-out rooms or personal email introductions).
High visibility of presentations after GPS 2025: Over 60 scientific presentations (including sponsored talks) and four abstracts with the highest reviewers’ ratings were published online in a video format by Grand Rounds in Urology (GRU) within several weeks after the event. AdMeTech and GRU dedicated newsletters – highlighting individual talks – ensure a joint outreach to over 21,000 physicians. GRU leadership and staff pointed out consistently since 2019 that the published GPS presentations have had a high viewing rate.
PLANS FOR GPS 2026: To address a full spectrum of patient care strategies:
- Current and future advances in screening and clinical evaluation of men prior to diagnosis of prostate cancer (PC)
- Selection of patients for biopsies and improved tissue sampling
- Improved diagnosis of localized PC and selection of patients for appropriate care (e.g., active surveillance, image-targeted partial ablation, or immediate whole-gland treatment, such as radical surgery or radiation)
- Improved diagnosis and treatment of recurrent and advanced PC, including oligometastatic and systemic metastatic disease
- Expanded discussion on the priority research needs in image-guided, minimally invasive treatment and emerging data on its clinical utility compared to other clinical interventions
- Increased participation of the organizations leading training, accreditation, regulatory and reimbursement policies to expedite clinical evaluation and adoption of promising novel diagnostics and therapeutics
- Role of precision care in reducing health disparities; and
- Discussion of the emerging role of bioinformatics, artificial intelligence, machine and deep learning for management and implementation of integrated multi-modality diagnostics for predictive and prognostic modeling that in turn, is expected to be critical for selecting individualized management strategies.
FOR MORE INFORMATION: To learn more about the background and history of GPS in general, GPS 2025, and plans for GPS 2026, please visit here.